BioSyngen Pte Ltd.
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.biosyngen.com
BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
Early Phase 1
Not yet recruiting
- Conditions
- Colorectal CancerPancreatic Cancer
- Interventions
- Biological: Group ABiological: Group B
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT06645301
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: Single drug group ABiological: Combined treatment group B
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT06643910
- Locations
- 🇨🇳
Yuqing Li, Shenzhen, Guangdong, China
Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma
Early Phase 1
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: Group ABiological: Group B
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06645314
A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer
Phase 1
Recruiting
- Conditions
- Locally Advanced Liver Carcinoma
- Interventions
- Biological: BST02
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 9
- Registration Number
- NCT06526832
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer
Early Phase 1
Not yet recruiting
- Conditions
- Locally Advanced/Metastatic Liver Cancer
- Interventions
- Biological: BST02 Injection
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT06173726
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
Early Phase 1
Recruiting
- Conditions
- Gastrointestinal Tumors
- Interventions
- Biological: First doseBiological: Second doseBiological: The third doseBiological: The fourth dose
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT06152757
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma
Phase 1
Completed
- Conditions
- EBV-positive Nasopharyngeal Carcinoma
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT05864924
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- BioSyngen Pte Ltd
- Target Recruit Count
- 58
- Registration Number
- NCT03736122
- Locations
- 🇦🇺
Flinders Medical Centre, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath